A large study assessing more than 1,000 CNS tumors of various types identified a 7% incidence of BRAF mutations (most commonly in pleomorphic xanthoastrocytoma (PXA) and World Health Organization (WHO) grade 1 ganglioglioma subtypes) (1). The gene discussed is BRAF; the disease is central nervous system neoplasm.